Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Gains from Investment Securities: 2022-2025

Historic Gains from Investment Securities for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $809,300.

  • Stoke Therapeutics' Gains from Investment Securities rose 10.97% to $809,300 in Q3 2025 from the same period last year, while for Sep 2025 it was $809,300, marking a year-over-year increase of 10.97%. This contributed to the annual value of $8.0 million for FY2024, which is 23.41% up from last year.
  • Latest data reveals that Stoke Therapeutics reported Gains from Investment Securities of $809,300 as of Q3 2025, which was up 98.61% from $407,482 recorded in Q2 2025.
  • Stoke Therapeutics' Gains from Investment Securities' 5-year high stood at $8.3 million during Q4 2022, with a 5-year trough of $79,400 in Q3 2022.
  • Moreover, its 3-year median value for Gains from Investment Securities was $897,712 (2024), whereas its average is $1.5 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first crashed by 89.11% in 2023, then surged by 787.26% in 2024.
  • Over the past 4 years, Stoke Therapeutics' Gains from Investment Securities (Quarterly) stood at $8.3 million in 2022, then crashed by 89.11% to $901,000 in 2023, then skyrocketed by 787.26% to $8.0 million in 2024, then rose by 10.97% to $809,300 in 2025.
  • Its Gains from Investment Securities was $809,300 in Q3 2025, compared to $407,482 in Q2 2025 and $2.0 million in Q1 2025.